Stocks / AMEX / Theriva Biologics Inc.

Theriva Biologics Inc.

Our Opinion

Theriva Biologics Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.

Supporting Evidence:

The company stated in the following press release that they use animals for drug testing.

“To assess the potential of SYN-005 to prevent pertussis, a non-human primate study was designed to determine if administration of hu1B7, one component of SYN-005, at two days of age could protect animals from a subsequent pertussis infection.” Read the following article

Company Description

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Company Website: